antibody contract manufacturing market is projected to reach USD 17 billion by 2030

February 16, 2021

With over 100 therapeutic monoclonal antibodies and antibody-based products in the market, the demand for developing and manufacturing of such products is anticipated to increase beyond the capabilities of innovator companies alone


Roots Analysis has announced the addition of the “Antibody Contract Manufacturing Market, 2020-2030” report to its list of offerings.


Although biopharmaceuticals offer significant profit margins and have been proven to be effective in treating a myriad of diseases, they are generally associated with high costs of development and complex manufacturing protocols; this is true for antibody-based products as well. Presently, there are a number of companies that claim to offer end-to-end solutions, ranging from antibody development to commercial production. Further, prevalent trends suggest that sponsor companies are likely to continue relying on contract service providers for various aspects of antibody-based product development and manufacturing.


To order this 285+ page report, which features 100+ figures and 110+ tables, please visit this link



North America and Europe are anticipated to capture over 70% of the market share by 2030

However, the market in the Asia is anticipated to grow at a relatively faster rate. Further, presently, more than 90% of the antibodies are being developed using mammalian expression systems, and this trend is unlikely to change significantly in short to mid-term.


To request a sample copy / brochure of this report, please visit this link      




Gaurav Chaudhary

+1 (415) 800 3415

+44 (122) 391 1091



Article Categories:

Leave a Comment